Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1626 1654
This examiner grants 76% of resolved cases
Sagar S. Patel serves in Tech Center 1600 and Art Unit 1626. He has overseen 474 resolved cases, maintaining an allowance rate of 75.7%. This rate suggests that a high percentage of the applications he handles result in a patent grant. The median days to allowance for these successful applications is 931. A significant feature of his prosecution profile is the interview lift of 34.6%.
This figure indicates that interviews are strongly associated with a higher chance of securing an allowance. Practitioners should view an interview as a primary tool for advancing prosecution in Art Unit 1626. The 474 resolved cases offer a robust data set for strategic decision-making. The combination of a 75.7% allowance rate and a 34.6% interview lift points to a prosecution environment where active dialogue with the examiner is highly beneficial. Applicants can expect a median timeline of 931 days for their applications to reach a final grant. Proactive engagement is key with this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17093833 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | Final Rejection | Merck Sharp & Dohme LLC |
| 18840382 | SYNTHESIS METHOD FOR ALKYLENE CARBONATE | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 18670859 | NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER | Non-Final OA | Novartis AG |
| 18676998 | COMPOSITION COMPRISING PIP4K2C INHIBITOR AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | Non-Final OA | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18593673 | ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF | Non-Final OA | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS |
| 18403664 | METHODS OF TREATING NEURODEGENERATIVE DISEASES OR CONDITIONS | Non-Final OA | The Salk Institute for Biological Studies |
| 18689533 | PROCESS FOR PURIFYING MESO-LACTIDE | Non-Final OA | PURAC BIOCHEM B.V. |
| 18030757 | Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof | Final Rejection | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy